It has been proposed that SRC-1 shifts steroid-responsive cancers to a steroid resistant status in which ADAM22 as the SRC-1 target gene has a crucial role, expressing it as a target of prognosis and a therapeutic drug that can contribute to the improvement of endocrine-resistant BC treatment. Here, SRC is linked to cancer.